Tweet
HC Wainwright set a $30.00 target price on Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Monday. The firm currently has a buy rating on the biopharmaceutical company's stock.
ABEO has been the subject of several other research reports. Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the stock a buy rating in a research note on Monday, May 14th. Seaport Global Securities assumed coverage on Abeona Therapeutics in a research note on Tuesday, June 5th. They set a buy rating and a $29.00 target price for the company. Cantor Fitzgerald restated a buy rating and set a $36.00 target price on shares of Abeona Therapeutics in a research note on Saturday, August 11th. ValuEngine upgraded Abeona Therapeutics from a hold rating to a buy rating in a research note on Friday, June 1st. Finally, BidaskClub upgraded Abeona Therapeutics from a hold rating to a buy rating in a research note on Thursday, June 28th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $28.30. Get Abeona Therapeutics alerts:
ABEO stock opened at $13.70 on Monday. The company has a market cap of $645.72 million, a P/E ratio of -20.76 and a beta of 1.37. Abeona Therapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $22.75. Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $1.81 million. Abeona Therapeutics had a negative return on equity of 23.02% and a negative net margin of 881.74%. analysts forecast that Abeona Therapeutics will post -0.71 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Knott David M purchased a new stake in Abeona Therapeutics in the first quarter valued at approximately $101,000. Fortaleza Asset Management Inc. purchased a new stake in Abeona Therapeutics in the second quarter valued at approximately $104,000. Virginia Retirement Systems ET AL purchased a new stake in Abeona Therapeutics in the first quarter valued at approximately $152,000. Sabby Management LLC purchased a new stake in Abeona Therapeutics in the first quarter valued at approximately $187,000. Finally, MetLife Investment Advisors LLC purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $194,000. Institutional investors own 69.29% of the company's stock.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B